Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.